Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients

Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients: An Open Labelled, Randomized, Multicentered, Controlled Trial

The purpose of this study is to ascertain whether Arotinolol Hydrochloride reduces mortality and cardiovascular events in chronic kidney disease stage 5 patients with hypertension.

Inclusion Criteria:

• Aged between 18-75 years-old;
• Chronic kidney disease stage 5 with haemodialysis treatment for 2 months;
• Patients with blood pressure≥140/90 mmHg after receiving 2 or 3 antihypertensive medications for 2 weeks;
• Patients who receiving alfa or beta blockers will be washed out for 2 weeks;
• Written informed consent

Exclusion Criteria:

• Unstable angina, myocardial infarction, symptomatic or continuous arrhythmia, cardiosurgery in the last 2 months;
• Patients who taking class I antiarrhythmic drugs;
• Resting heart rate less than 60;
• Patients with systolic pressure less than 90 mmHg;
• Patients with chronic obstructive pulmonary disease and asthma;
• Patients with cerebral infarction in the last 2 weeks;
• Severe disorders of liver function;
• Allergy to the arotinolol;
• Patients who planning to have kidney transplantation in the near future;
• Pregnancy and breast-feeding;
• Malignant tumor